胸腺法新对结直肠癌术后化疗患者免疫功能及生活质量影响.docVIP

胸腺法新对结直肠癌术后化疗患者免疫功能及生活质量影响 　　[摘要] 目的 探讨胸腺法新对结直肠癌术后化疗患者免疫功能及生活质量的影响。 方法 2009年5月～2014年7月间结直肠癌术后患者81例在本院行化疗，其中40例患者接受化疗同时接受胸腺法新1.6 mg 皮下注射，一周2次，直到化疗结束（联合组），其余 41例患者仅接受化疗（对照组）。比较两组患者细胞免疫及生活质量。 结果 联合组在化疗第3个月开始CD4+% 明显高于对照组（P0.05）；联合组在化疗第2个月开始CD8+%明显低于对照组（P0.05）；联合组在化疗第2个月开始CD4+/CD8+明显高于对照组（P0.05）。联合组在化疗第3个月开始KPS评分明显高于对照组（P0.05）。 结论 胸腺法新能明显提高结直肠癌术后化疗患者的免疫功能及生活质量。 　　[关键词] 结肠癌；化疗；免疫功能；直肠癌；生活质量 　　[中图分类号] R735.37 [文献标识码] B [文章编号] 1673-9701（2018）06-0082-04 　　[Abstract] Objective To investigate the effect of thymalfasin on immune function and quality of life in patients of colorectal cancer with postoperative chemotherapy. Methods From May 2009 to July 2014， 81 patients with colorectal cancer undergoing postoperative chemotherapy in our hospital were selected. 40 patients underwent chemotherapy combined with 1.6 mg subcutaneous injection of thymalfasin twice a week until chemotherapy was completed （the combined group）. The remaining 41 patients received chemotherapy alone（the control group）. The cellular immunity and quality of life of the two groups were compared. Results The CD4+% in the combined group was significantly higher than the control group at the third month of chemotherapy（P0.05）. The combined group had a significantly lower level of CD8+% than the control group at the second month of chemotherapy（P0.05）. CD4+/CD8+ in the second month was significantly higher than the control group （P0.05）. The KPS score of the combined group at the third month was significantly higher than the control group（P0.05）. Conclusion Thymalfasin can significantly improve the immune function and quality of life in patients of colorectal cancer with postoperative chemotherapy. 　　[Key words] Colon cancer； Chemotherapy； Immune function； Rectal cancer； Quality of life 　　?Y直肠癌是我国常见的消化道恶性肿瘤，发病率居我国恶性肿瘤的第四位，并有逐渐上升的趋势[1]。目前针对结直肠癌最有效的治疗手段是根治切除，而进展期结直肠癌术后通常会出现复发转移，因此需要在术后进行辅助化疗以减少术后复发转移，延长患者长期生存[2]。但是手术创伤已经损害了患者免疫功能，而术后化疗则进一步削弱了机体的免疫功能[3-5]。而当机体的免疫功能下降或受到损害时，肿瘤生长速度和出现转移的机会就会升高[6]。胸腺法新是临床常用的免疫增